Vascular Endothelial Growth Factor-Trap Suppresses Tumorigenicity of Multiple Pancreatic Cancer Cell Lines

@article{Fukasawa2004VascularEG,
  title={Vascular Endothelial Growth Factor-Trap Suppresses Tumorigenicity of Multiple Pancreatic Cancer Cell Lines},
  author={Mitsuharu Fukasawa and Murray Korc},
  journal={Clinical Cancer Research},
  year={2004},
  volume={10},
  pages={3327 - 3332}
}
  • M. Fukasawa, M. Korc
  • Published 15 May 2004
  • Biology, Chemistry, Medicine
  • Clinical Cancer Research
Purpose: Vascular endothelial growth factor A (VEGF-A) is a potent angiogenic agent that binds to two high affinity VEGF receptors (VEGFRs), a process facilitated by the low affinity neuropilin receptors. Although VEGF-A is overexpressed in pancreatic ductal adenocarcinoma, it is not known whether the in vivo growth of multiple pancreatic cancer cells can be efficiently blocked by VEGF-A sequestration. Experimental Design: Four human pancreatic cancer cell lines were grown s.c. in athymic nude… 
View on AACR
clincancerres.aacrjournals.org
116 Citations
Highly Influential Citations
1
Background Citations
36
Methods Citations
4
Results Citations
1

116 Citations

Citation Type

Citation Type

Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway.
TLDR
It is demonstrated that in cancer patients high expression of VEGF is correlated with metastasis, and anti-VEGF treatment (bevacizumab) has clinical effects on tumor metastasis and the blockade of V EGF-VEGFR1-induced metastasis may provide a novel approach for the prevention and treatment of tumor metastases.
Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
TLDR
Several drugs currently in development target the vascular endothelial growth factor (VEGF) pathway, a validated target in the treatment of non–small cell lung cancer (NSCLC) and the activity of single-agent VEGF Trap in NSCLC is being assessed in a multicenter phase II trial.
Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
TLDR
This review will focus on patents which target VEGF-[A-F] and/or VEGFR-[1-3] for use in anti-cancer treatment and the potential for combinatorial therapies.
Suppression of angiogenesis and tumor growth by recombinant T4 phages displaying extracellular domain of vascular endothelial growth factor receptor 2
TLDR
In conclusion, this study reveals that the recombinant T4-VEGFR2 phages generated using T 4-based phage display system can inhibit VEGF-mediated tumor angiogenesis and the T4phage display technology can therefore be used for the development of novel anti-cancer strategies.
Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells.
TLDR
Downregulation of GPC1 in the human pancreatic cancer cell line PANC-1, using antisense approaches, resulted in prolonged doubling times and decreased anchorage-independent growth in vitro as well as attenuated tumor growth, angiogenesis, and metastasis when these cells were transplanted into athymic mice.
Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis.
TLDR
These studies implicate CTGF as a new target in pancreatic cancer and suggest that inhibition of CTGF with a human monoclonal antibody may control primary and metastatic tumor growth.
Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
TLDR
In a highly metastatic human hepatocellular carcinoma model in severe combined immunodeficient mice, VEGFR31-Ig potently blocked both tumor angiogenesis and lymphangiogenesis, effectively inhibiting primary tumor growth and metastasis to lungs and lymph nodes.
Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
TLDR
By providing comprehensive real-time information, molecular imaging of VEGF pathway may accelerate the drug development process and will be of great help for patient stratification and therapeutic effect monitoring, which will promote effective personalized molecular cancer therapy.
Connective tissue growth factor–specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer
TLDR
It is suggested that CTGF may contribute to aberrant autocrine and paracrine pathways that promote pancreatic cancer cell growth, invasion, metastasis, and angiogenesis and blocking CTGF actions with FG-3019 may represent a novel therapeutic approach in pancreatic ductal adenocarcinoma.
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 62 REFERENCES
Pancreatic cancer cell‐derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo
TLDR
The hypothesis that VEGF promotes pancreatic cancer growth in vivo is supported and anti‐VEGF therapy may be useful in the treatment of this disease is suggested.
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
  • A. Byrne, Leorah H. Ross, +5 authors R. Jaffe
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
TLDR
Systemic administration of the V EGF-Trap, a recently described high-affinity soluble decoy receptor for VEGF, prevents ascites accumulation and also inhibits the growth of disseminated cancer.
Gene Therapy for Pancreatic Cancer Using an Adenovirus Vector Encoding Soluble flt-1 Vascular Endothelial Growth Factor Receptor
TLDR
The regional tumor suppression effect of adenovirus-mediated soluble flt-1 in human pancreatic cancer cells is demonstrated and indicates that antiangiogenic gene therapy using soluble flT-1 might be an effective approach for Pancic cancer treatment.
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma
TLDR
It is found that early in tumor formation, cooption of host vasculature occurs, and that persistence of this effect is related to the degree of blockade of VEGF activity.
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.
  • J. Itakura, T. Ishiwata, +4 authors M. Korc
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
TLDR
The findings indicate that VEGF is commonly overexpressed in human pancreatic cancers and that this factor may contribute to the angiogenic process and tumor growth in this disorder.
VEGF-Trap: A VEGF blocker with potent antitumor effects
  • J. Holash, S. Davis, +16 authors J. Rudge
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2002
TLDR
This work has engineer a very potent high-affinity VEGF blocker that has markedly enhanced pharmacokinetic properties and effectively suppresses tumor growth and vascularization in vivo, resulting in stunted and almost completely avascular tumors.
Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells.
We identify a novel function for the vascular endothelial growth factor (VEGF) in its ability to stimulate an autocrine signaling pathway in metastatic breast carcinoma cells that is essential for…
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade
TLDR
It is reported that high-affinity blockade of VEGF, using the recently described V EGF-Trap, abolishes mature, preexisting vasculature in established xenografts, and may provide a new therapeutic option for patients with bulky, metastatic cancers.
De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop.
TLDR
The results not only support the important role of the VEGF/VEGF receptor system in pancreatic tumor biology but also suggest the existence of an autocrine/paracrine mitogenic loop for pancreatic cancer cells.
Vascular endothelial growth factor (VEGF) and its receptors
TLDR
Recent developments that have widened considerably the understanding of the mechanisms that control V EGF production and VEGF signal transduction are focused on and recent studies that have shed light on the mechanisms by which VEGf regulates angiogenesis are reviewed.
...
1
2
3
4
5
...